Clinical and Morphologic Characteristics of MEK Inhibitor-Associated Retinopathy. Differences from Central Serous Chorioretinopathy
Clinical Trials, Phase I as Topic
The subretinal fluid foci associated with MEK inhibitors have unique clinical and morphologic characteristics, which can be distinguished from the findings of central serous chorioretinopathy. In this series, MEK inhibitors did not cause irreversible loss of vision or serious eye damage.